{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T03:44:44Z","timestamp":1782963884430,"version":"3.54.5"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"AstraZeneca"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-026-10651-1","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T02:44:40Z","timestamp":1782960280000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Overcoming barriers to early diagnosis and treatment of p.Val142Ile amyloid transthyretin (ATTR) cardiomyopathy"],"prefix":"10.1007","volume":"31","author":[{"given":"Keith C.","family":"Ferdinand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senthil","family":"Selvaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"issue":"1","key":"10651_CR1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13023-025-03547-0","volume":"20","author":"D Delgado","year":"2025","unstructured":"Delgado D, Dabbous F, Shivappa N, Mazhar F, Wittbrodt E, Shridharmurthy D et al (2025) Epidemiology of transthyretin (ATTR) amyloidosis: a systematic literature review. Orphanet J Rare Dis 20(1):29. https:\/\/doi.org\/10.1186\/s13023-025-03547-0","journal-title":"Orphanet J Rare Dis"},{"key":"10651_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.09.004","author":"MM Kittleson","year":"2025","unstructured":"Kittleson MM, Ambardekar AV, Cheng RK, Griffin JM, Maurer MS, Nativi-Nicolau J et al (2025) Transthyretin cardiac amyloidosis evaluation and management: 2025 ACC concise clinical guidance. J Am Coll Cardiol. 87(5):549\u2013565 https:\/\/doi.org\/10.1016\/j.jacc.2025.09.004","journal-title":"J Am Coll Cardiol"},{"key":"10651_CR3","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2025.2948","author":"FL Ruberg","year":"2025","unstructured":"Ruberg FL, Teruya S, Helmke S, Smiley DA, Fine D, Kurian D et al (2025) Transthyretin cardiac amyloidosis in older Black and Hispanic individuals with heart failure. JAMA Cardiol 10(10):1035\u20131043. https:\/\/doi.org\/10.1001\/jamacardio.2025.2948","journal-title":"JAMA Cardiol"},{"issue":"9","key":"10651_CR4","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1001\/jama.2024.0442","volume":"331","author":"FL Ruberg","year":"2024","unstructured":"Ruberg FL, Maurer MS (2024) Cardiac amyloidosis due to transthyretin protein: a review. JAMA 331(9):778\u2013791. https:\/\/doi.org\/10.1001\/jama.2024.0442","journal-title":"JAMA"},{"issue":"2","key":"10651_CR5","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1002\/ehf2.15143","volume":"12","author":"AS Antonopoulos","year":"2025","unstructured":"Antonopoulos AS, Tsampras T, Lazaros G, Tsioufis K, Vlachopoulos C (2025) A phenomap of TTR amyloidosis to aid diagnostic screening. ESC Heart Fail 12(2):1113\u20131118. https:\/\/doi.org\/10.1002\/ehf2.15143","journal-title":"ESC Heart Fail"},{"issue":"1","key":"10651_CR6","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s13023-022-02359-w","volume":"17","author":"A Dispenzieri","year":"2022","unstructured":"Dispenzieri A, Coelho T, Concei\u00e7\u00e3o I, Waddington-Cruz M, Wixner J, Kristen AV et al (2022) Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update. Orphanet J Rare Dis 17(1):236. https:\/\/doi.org\/10.1186\/s13023-022-02359-w","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"10651_CR7","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1007\/s00415-019-09688-0","volume":"268","author":"D Adams","year":"2021","unstructured":"Adams D, Ando Y, Beirao JM, Coelho T, Gertz MA, Gillmore JD et al (2021) Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol 268(6):2109\u20132122. https:\/\/doi.org\/10.1007\/s00415-019-09688-0","journal-title":"J Neurol"},{"issue":"1","key":"10651_CR8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13023-017-0726-x","volume":"13","author":"Y Sekijima","year":"2018","unstructured":"Sekijima Y, Ueda M, Koike H, Misawa S, Ishii T, Ando Y (2018) Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm. Orphanet J Rare Dis 13(1):6. https:\/\/doi.org\/10.1186\/s13023-017-0726-x","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"10651_CR9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","volume":"68","author":"MS Maurer","year":"2016","unstructured":"Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B et al (2016) Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol 68(2):161\u2013172. https:\/\/doi.org\/10.1016\/j.jacc.2016.03.596","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"10651_CR10","doi-asserted-by":"publisher","first-page":"e033770","DOI":"10.1161\/jaha.123.033770","volume":"13","author":"K Bhatt","year":"2024","unstructured":"Bhatt K, Delgado DH, Khella S, Bumma N, Karam C, Keller A et al (2024) Hereditary transthyretin amyloidosis in patients referred to a genetic testing program. J Am Heart Assoc 13(23):e033770. https:\/\/doi.org\/10.1161\/jaha.123.033770","journal-title":"J Am Heart Assoc"},{"issue":"15","key":"10651_CR11","doi-asserted-by":"publisher","first-page":"e028973","DOI":"10.1161\/jaha.122.028973","volume":"12","author":"A Madhani","year":"2023","unstructured":"Madhani A, Sabogal N, Massillon D, Paul LD, Rodriguez C, Fine D et al (2023) Clinical penetrance of the transthyretin V122I variant in older black patients with heart failure: the SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study. J Am Heart Assoc 12(15):e028973. https:\/\/doi.org\/10.1161\/jaha.122.028973","journal-title":"J Am Heart Assoc"},{"issue":"21","key":"10651_CR12","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1001\/jama.2024.4467","volume":"331","author":"S Selvaraj","year":"2024","unstructured":"Selvaraj S, Claggett B, Shah SH, Mentz RJ, Khouri MG, Manichaikul AW et al (2024) Cardiovascular burden of the V142I transthyretin variant. JAMA 331(21):1824\u20131833. https:\/\/doi.org\/10.1001\/jama.2024.4467","journal-title":"JAMA"},{"issue":"1","key":"10651_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/13506129.2018.1556156","volume":"26","author":"I Concei\u00e7\u00e3o","year":"2019","unstructured":"Concei\u00e7\u00e3o I, Damy T, Romero M, Gal\u00e1n L, Attarian S, Luigetti M et al (2019) Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations. Amyloid 26(1):3\u20139. https:\/\/doi.org\/10.1080\/13506129.2018.1556156","journal-title":"Amyloid"},{"issue":"11","key":"10651_CR14","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","volume":"81","author":"MM Kittleson","year":"2023","unstructured":"Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, Clarke JO et al (2023)ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the american college of cardiology solution set oversight committee. J Am Coll Cardiol 81(11):1076\u20131126. https:\/\/doi.org\/10.1016\/j.jacc.2022.11.022","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10651_CR15","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1080\/13506129.2020.1764928","volume":"27","author":"O Akinboboye","year":"2020","unstructured":"Akinboboye O, Shah K, Warner AL, Damy T, Taylor HA, Gollob J et al (2020) DISCOVERY: prevalence of transthyretin (TTR) mutations in a US-centric patient population suspected of having cardiac amyloidosis. Amyloid 27(4):223\u2013230. https:\/\/doi.org\/10.1080\/13506129.2020.1764928","journal-title":"Amyloid"},{"issue":"22","key":"10651_CR16","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2019.17935","volume":"322","author":"SM Damrauer","year":"2019","unstructured":"Damrauer SM, Chaudhary K, Cho JH, Liang LW, Argulian E, Chan L et al (2019) Association of the V122I hereditary transthyretin amyloidosis genetic variant with heart failure among individuals of African or Hispanic\/Latino ancestry. JAMA 322(22):2191\u20132202. https:\/\/doi.org\/10.1001\/jama.2019.17935","journal-title":"JAMA"},{"issue":"2","key":"10651_CR17","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/mus.28301","volume":"71","author":"E Jacoby","year":"2025","unstructured":"Jacoby E, Quan D, Todd E, Shortt J, Smith H, Rafaels N et al (2025) Prevalence of pathogenic transthyretin gene variants in the Rocky Mountain region. Muscle Nerve 71(2):252\u2013256. https:\/\/doi.org\/10.1002\/mus.28301","journal-title":"Muscle Nerve"},{"issue":"2","key":"10651_CR18","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/mus.28414","volume":"72","author":"U Desai","year":"2025","unstructured":"Desai U, Ilieva HS, Eyer JE, Peltier AC (2025) Peripheral nervous system involvement of hereditary transthyretin amyloidosis in the United States: a multi-center perspective. Muscle Nerve 72(2):286\u2013293. https:\/\/doi.org\/10.1002\/mus.28414","journal-title":"Muscle Nerve"},{"issue":"4","key":"10651_CR19","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.123.033094","volume":"13","author":"A Ioannou","year":"2024","unstructured":"Ioannou A, Nitsche C, Porcari A, Patel RK, Razvi Y, Rauf MU et al (2024) Multiorgan dysfunction and associated prognosis in transthyretin cardiac amyloidosis. J Am Heart Assoc 13(4):e033094. https:\/\/doi.org\/10.1161\/jaha.123.033094","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"10651_CR20","doi-asserted-by":"publisher","DOI":"10.1161\/circgen.124.004911","volume":"18","author":"JL Grodin","year":"2025","unstructured":"Grodin JL, Gupta A, Rison I Jr., Kozlitina J, Saelices-Gomez L, Girotra S et al (2025) Risk for heart failure and atrial fibrillation across the lifespan for carriers of the amyloidogenic p.V142I TTR variant. Circ Genom Precis Med 18(4):e004911. https:\/\/doi.org\/10.1161\/circgen.124.004911","journal-title":"Circ Genom Precis Med"},{"issue":"2","key":"10651_CR21","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jchf.2021.09.006","volume":"10","author":"AC Coniglio","year":"2022","unstructured":"Coniglio AC, Segar MW, Loungani RS, Savla JJ, Grodin JL, Fox ER et al (2022) Transthyretin V142I genetic variant and cardiac remodeling, injury, and heart failure risk in black adults. JACC Heart Fail 10(2):129\u2013138. https:\/\/doi.org\/10.1016\/j.jchf.2021.09.006","journal-title":"JACC Heart Fail"},{"issue":"14","key":"10651_CR22","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1001\/jama.2022.2896","volume":"327","author":"V Parcha","year":"2022","unstructured":"Parcha V, Malla G, Irvin MR, Armstrong ND, Judd SE, Lange LA et al (2022) Association of transthyretin Val122Ile variant with incident heart failure among Black individuals. JAMA 327(14):1368\u20131378. https:\/\/doi.org\/10.1001\/jama.2022.2896","journal-title":"JAMA"},{"issue":"7","key":"10651_CR23","doi-asserted-by":"publisher","DOI":"10.1161\/circheartfailure.125.013212","volume":"18","author":"VN Rao","year":"2025","unstructured":"Rao VN, Claggett BL, Khouri MG, Shah AM, Solomon SD, Selvaraj S (2025) Late-life echocardiographic effects of the amyloidogenic p.V142I transthyretin variant. Circ Heart Fail 18(7):e013212. https:\/\/doi.org\/10.1161\/circheartfailure.125.013212","journal-title":"Circ Heart Fail"},{"issue":"1","key":"10651_CR24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jacc.2021.04.042","volume":"78","author":"S Selvaraj","year":"2021","unstructured":"Selvaraj S, Claggett B, Minamisawa M, Windham BG, Chen LY, Inciardi RM et al (2021) Atrial fibrillation and ischemic stroke with the amyloidogenic V122I transthyretin variant among Black Americans. J Am Coll Cardiol 78(1):89\u201391. https:\/\/doi.org\/10.1016\/j.jacc.2021.04.042","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10651_CR25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jaccao.2025.12.006","volume":"8","author":"K Sideris","year":"2026","unstructured":"Sideris K, Nelson TJ, Brinker L, Gao A, Tcheandjieu C, Kyriakopoulos CP et al (2026) Systemic manifestations and mortality risk in transthyretin V142I variant carriers: a million veteran program analysis. JACC Cardio Oncology 8(1):31\u201344. https:\/\/doi.org\/10.1016\/j.jaccao.2025.12.006","journal-title":"JACC Cardio Oncology"},{"issue":"22","key":"10651_CR26","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1161\/circulationaha.122.060852","volume":"146","author":"A Ioannou","year":"2022","unstructured":"Ioannou A, Patel RK, Razvi Y, Porcari A, Sinagra G, Venneri L et al (2022) Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years. Circulation 146(22):1657\u20131670. https:\/\/doi.org\/10.1161\/circulationaha.122.060852","journal-title":"Circulation"},{"issue":"3","key":"10651_CR27","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s10741-021-10080-2","volume":"27","author":"J Nativi-Nicolau","year":"2022","unstructured":"Nativi-Nicolau J, Karam C, Khella S, Maurer M (2022) Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness. Heart Fail Rev 27(3):785\u2013793. https:\/\/doi.org\/10.1007\/s10741-021-10080-2","journal-title":"Heart Fail Rev"},{"issue":"1","key":"10651_CR28","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13023-021-01706-7","volume":"16","author":"D Rintell","year":"2021","unstructured":"Rintell D, Heath D, Braga Mendendez F, Cross E, Cross T, Knobel V et al (2021) Patient and family experience with transthyretin amyloid cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN) amyloidosis: results of two focus groups. Orphanet J Rare Dis 16(1):70. https:\/\/doi.org\/10.1186\/s13023-021-01706-7","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"10651_CR29","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jacc.2025.10.021","volume":"87","author":"G Spencer-Bonilla","year":"2026","unstructured":"Spencer-Bonilla G, Fan J, Cheng P, Varshney A, Din N, Rodriguez F et al (2026) Delayed diagnosis of transthyretin amyloid cardiomyopathy in the veterans health administration. J Am Coll Cardiol 87(5):533\u2013545. https:\/\/doi.org\/10.1016\/j.jacc.2025.10.021","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10651_CR30","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1001\/jamacardio.2026.0833","volume":"11","author":"G Spencer-Bonilla","year":"2026","unstructured":"Spencer-Bonilla G, Fan J, Cheng P, Din N, Rodriguez F, Davies M et al (2026) Timeliness of transthyretin cardiac amyloidosis diagnosis in the Medicare population. JAMA Cardiol 11(6):524\u2013533. https:\/\/doi.org\/10.1001\/jamacardio.2026.0833","journal-title":"JAMA Cardiol"},{"issue":"9","key":"10651_CR31","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/jamacardio.2018.2093","volume":"3","author":"KM Alexander","year":"2018","unstructured":"Alexander KM, Orav J, Singh A, Jacob SA, Menon A, Padera RF et al (2018) Geographic disparities in reported us amyloidosis mortality from 1979 to 2015: potential underdetection of cardiac amyloidosis. JAMA Cardiol 3(9):865\u2013870. https:\/\/doi.org\/10.1001\/jamacardio.2018.2093","journal-title":"JAMA Cardiol"},{"issue":"3","key":"10651_CR32","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jchf.2024.11.021","volume":"13","author":"G Fahed","year":"2018","unstructured":"Fahed G, Jimenez JI, Cai N, Wu X, Edmonds A, Shah K et al (2018) Socioeconomic and geographic disparities in the reported U.S. amyloidosis mortality from 2018-2022: a persistent under detection? JACC Heart Fail 13(3):533\u2013535. https:\/\/doi.org\/10.1016\/j.jchf.2024.11.021","journal-title":"JACC Heart Fail"},{"issue":"6","key":"10651_CR33","doi-asserted-by":"publisher","first-page":"e005407","DOI":"10.1161\/circheartfailure.118.005407","volume":"12","author":"LG Gilstrap","year":"2019","unstructured":"Gilstrap LG, Dominici F, Wang Y, El-Sady MS, Singh A, Di Carli MF et al (2019) Epidemiology of cardiac amyloidosis-associated heart failure hospitalizations among fee-for-service medicare beneficiaries in the United States. Circ Heart Fail 12(6):e005407. https:\/\/doi.org\/10.1161\/circheartfailure.118.005407","journal-title":"Circ Heart Fail"},{"issue":"8","key":"10651_CR34","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1007\/s10554-025-03436-4","volume":"41","author":"JL Ngouchet Nouhossi","year":"2025","unstructured":"Ngouchet Nouhossi JL, Minga I, Szasz T, Truong VT, Johnson AE, Yang E et al (2025) Disparities in diagnosis and outcomes in American patients with transthyretin cardiac amyloidosis. Int J Cardiovasc Imaging 41(8):1487\u20131496. https:\/\/doi.org\/10.1007\/s10554-025-03436-4","journal-title":"Int J Cardiovasc Imaging"},{"issue":"7","key":"10651_CR35","doi-asserted-by":"publisher","first-page":"e023895","DOI":"10.1161\/jaha.121.023895","volume":"11","author":"H Chen","year":"2022","unstructured":"Chen H, Chandrashekar P, Fischer K, Carlson D, Narayan U, Chen J et al (2022) Navigating the complex web of prescribing amyloidosis therapeutics: a primer. J Am Heart Assoc 11(7):e023895. https:\/\/doi.org\/10.1161\/jaha.121.023895","journal-title":"J Am Heart Assoc"},{"key":"10651_CR36","unstructured":"BridgeBio Pharma Inc. Attruby: Access & Support. 2026. https:\/\/attrubyhcp.com\/access-support.\u00a0Accessed 3 June 2026"},{"key":"10651_CR37","unstructured":"Alnylam Pharmaceuticals Inc. (2025) Alnylam Announces FDA Approval of AMVUTTRA\u00ae (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM). https:\/\/investors.alnylam.com\/press-release?id=28831.\u00a0Accessed 29 June 2026"},{"key":"10651_CR38","doi-asserted-by":"publisher","DOI":"10.1161\/circ.152.suppl_3.4369360","author":"N Bart","year":"2025","unstructured":"Bart N, Judge D, Udall M, Hennum L, Falvey H, Rosen A et al (2025) Abstract 4369360: vutrisiran healthcare resource utilization, costs, discontinuation, and mortality: a retrospective database analysis. Circulation. https:\/\/doi.org\/10.1161\/circ.152.suppl_3.4369360","journal-title":"Circulation"},{"key":"10651_CR39","unstructured":"Amyloidosis Foundation (2025) Understanding coverage for AMVUTTRA\u00ae (vutrisiran). https:\/\/amyloidosis.org\/resources\/.\u00a0Accessed 16 Mar 2026"},{"key":"10651_CR40","unstructured":"ClinicalTrials.gov (2026) DemonsTTRate: a global, observational, multicenter, long-term study of patients with ATTR-CM in a real-world setting (DemonsTTRate). https:\/\/clinicaltrials.gov\/study\/NCT07358078.\u00a0Accessed 16 Mar 2026"},{"issue":"3","key":"10651_CR41","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s40119-025-00402-y","volume":"14","author":"JD Gillmore","year":"2025","unstructured":"Gillmore JD, Hahn K, Smith JG, Concei\u00e7\u00e3o I, Tian Z, Grogan M et al (2025) Rationale and design of ANTHOLOGY: an ATTR amyloidosis real-world evidence program aiming to address gaps in amyloidosis care. Cardiol Ther 14(3):477\u2013490. https:\/\/doi.org\/10.1007\/s40119-025-00402-y","journal-title":"Cardiol Ther"},{"issue":"3","key":"10651_CR42","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.jchf.2024.11.022","volume":"13","author":"G Fahed","year":"2025","unstructured":"Fahed G, Jimenez JI, Adrianzen Fonseca MI, Hu J, Spencer-Bonilla G, Haddad F et al (2025) The impact of social determinants of health on timely detection in transthyretin cardiac amyloidosis. JACC: Heart Failure 13(3):530\u2013532. https:\/\/doi.org\/10.1016\/j.jchf.2024.11.022","journal-title":"JACC: Heart Failure"},{"issue":"24","key":"10651_CR43","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1093\/ajhp\/zxae183","volume":"81","author":"KM Walenczyk","year":"2024","unstructured":"Walenczyk KM, Singh A, Tong K, Burg MM, Miller EJ (2024) From transthyretin cardiac amyloidosis diagnosis to tafamidis treatment: association of drop-off with patient sociodemographic characteristics. Am J Health Syst Pharm 81(24):1245\u20131251. https:\/\/doi.org\/10.1093\/ajhp\/zxae183","journal-title":"Am J Health Syst Pharm"},{"issue":"4","key":"10651_CR44","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1096\/fba.2020-00116","volume":"3","author":"E Madu","year":"2021","unstructured":"Madu E, Mezue K, Madu K (2021) Social determinants and cardiovascular care: a focus on vulnerable populations and the Jamaica experience. FASEB Bioadv 3(4):266\u2013274. https:\/\/doi.org\/10.1096\/fba.2020-00116","journal-title":"FASEB Bioadv"},{"issue":"1","key":"10651_CR45","doi-asserted-by":"publisher","first-page":"59","DOI":"10.5334\/gh.1262","volume":"18","author":"D Brito","year":"2023","unstructured":"Brito D, Albrecht FC, de Arenaza DP, Bart N, Better N, Carvajal-Juarez I et al (2023) World Heart Federation consensus on transthyretin amyloidosis cardiomyopathy (ATTR-CM). Glob Heart 18(1):59. https:\/\/doi.org\/10.5334\/gh.1262","journal-title":"Glob Heart"},{"issue":"1","key":"10651_CR46","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/21548331.2021.2016334","volume":"50","author":"RM Ismailov","year":"1995","unstructured":"Ismailov RM, Lerut J, Ace\u00f1a \u00c1, Khasanova ZD (1995) Enhancing knowledge and awareness of transthyretin cardiac amyloidosis and shared decision-making among cardiology team members in Colorado, USA via an online educational initiative. Hosp Pract 50(1):37\u201341. https:\/\/doi.org\/10.1080\/21548331.2021.2016334","journal-title":"Hosp Pract"},{"issue":"1","key":"10651_CR47","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s40119-021-00219-5","volume":"10","author":"MH Rozenbaum","year":"2021","unstructured":"Rozenbaum MH, Large S, Bhambri R, Stewart M, Whelan J, van Doornewaard A et al (2021) Impact of delayed diagnosis and misdiagnosis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM): a targeted literature review. Cardiol Ther 10(1):141\u2013159. https:\/\/doi.org\/10.1007\/s40119-021-00219-5","journal-title":"Cardiol Ther"},{"issue":"18","key":"10651_CR48","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM et al (2022) 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145(18):e895\u2013e1032. https:\/\/doi.org\/10.1161\/CIR.0000000000001063","journal-title":"Circulation"},{"issue":"4","key":"10651_CR49","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jaccao.2021.07.002","volume":"3","author":"BJ Carry","year":"2021","unstructured":"Carry BJ, Young K, Fielden S, Kelly MA, Sturm AC, Avila JD et al (2021) Genomic screening for pathogenic transthyretin variants finds evidence of underdiagnosed amyloid cardiomyopathy from health records. JACC CardioOncol 3(4):550\u2013561. https:\/\/doi.org\/10.1016\/j.jaccao.2021.07.002","journal-title":"JACC CardioOncol"},{"issue":"11","key":"10651_CR50","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1001\/jamacardio.2024.2654","volume":"9","author":"JA Regan","year":"2024","unstructured":"Regan JA, Fontana M, Selvaraj S (2024) Genotype- vs phenotype-guided approaches to improve ATTR detection. JAMA Cardiol 9(11):957\u2013959. https:\/\/doi.org\/10.1001\/jamacardio.2024.2654","journal-title":"JAMA Cardiol"},{"issue":"1","key":"10651_CR51","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1185\/03007995.2012.754348","volume":"29","author":"T Coelho","year":"2013","unstructured":"Coelho T, Maurer MS, Suhr OB (2013) THAOS - the transthyretin amyloidosis outcomes survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin 29(1):63\u201376. https:\/\/doi.org\/10.1185\/03007995.2012.754348","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"10651_CR52","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.cardfail.2024.08.055","volume":"31","author":"JA Regan","year":"2025","unstructured":"Regan JA, Khouri MG, Olabisi OA, Alexander KM, Khan SS, Shah SH et al (2025) Should we systematically screen for the amyloidogenic V142I variant? J Card Fail 31(1):136\u2013139. https:\/\/doi.org\/10.1016\/j.cardfail.2024.08.055","journal-title":"J Card Fail"},{"issue":"3","key":"10651_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2024.101346","volume":"27","author":"AR Kontorovich","year":"2025","unstructured":"Kontorovich AR, Benson CB, McClellan A, Belbin GM, Kenny EE, Abul-Husn NS (2025) Evolving knowledge of red flag clinical features associated with TTR p.(Val142Ile) in a diverse electronic health-record-linked biobank. Genet Med 27(3):101346. https:\/\/doi.org\/10.1016\/j.gim.2024.101346","journal-title":"Genet Med"},{"issue":"23","key":"10651_CR54","doi-asserted-by":"publisher","first-page":"e036995","DOI":"10.1161\/jaha.124.036995","volume":"13","author":"NR Shah","year":"2024","unstructured":"Shah NR, Bellam N (2024) Improving health equity through standardization and selective expansion of genetic testing in transthyretin amyloidosis. J Am Heart Assoc 13(23):e036995. https:\/\/doi.org\/10.1161\/jaha.124.036995","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"10651_CR55","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1001\/jamacardio.2016.5864","volume":"2","author":"M Arvanitis","year":"2017","unstructured":"Arvanitis M, Koch CM, Chan GG, Torres-Arancivia C, LaValley MP, Jacobson DR et al (2017) Identification of transthyretin cardiac amyloidosis using serum retinol-binding protein 4 and a clinical prediction model. JAMA Cardiol 2(3):305\u2013313. https:\/\/doi.org\/10.1001\/jamacardio.2016.5864","journal-title":"JAMA Cardiol"},{"issue":"11 Pt 1","key":"10651_CR56","doi-asserted-by":"publisher","first-page":"102208","DOI":"10.1016\/j.jacadv.2025.102208","volume":"4","author":"D Terentes-Printzios","year":"2025","unstructured":"Terentes-Printzios D, Koilakou ME, Alexiou P, Antonopoulos A, Kasiakogias A, Katsimichas T et al (2025) Serum transthyretin as prognostic biomarker for cardiovascular events and mortality: a systematic review and meta-analysis. JACC Adv 4(11 Pt 1):102208. https:\/\/doi.org\/10.1016\/j.jacadv.2025.102208","journal-title":"JACC Adv"},{"issue":"1","key":"10651_CR57","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1038\/s41598-017-03096-y","volume":"7","author":"WT Chen","year":"2017","unstructured":"Chen WT, Lee MS, Chang CL, Chiu CT, Chang ML (2017) Retinol-binding protein-4 expression marks the short-term mortality of critically ill patients with underlying liver disease: lipid, but not glucose, matters. Sci Rep 7(1):2881. https:\/\/doi.org\/10.1038\/s41598-017-03096-y","journal-title":"Sci Rep"},{"key":"10651_CR58","doi-asserted-by":"publisher","first-page":"101979","DOI":"10.1016\/j.tranon.2024.101979","volume":"45","author":"F Wan","year":"2024","unstructured":"Wan F, Zhu Y, Wu F, Huang X, Chen Y, Zhou Y et al (2024) Retinol-binding protein 4 as a promising serum biomarker for the diagnosis and prognosis of hepatocellular carcinoma. Transl Oncol 45:101979. https:\/\/doi.org\/10.1016\/j.tranon.2024.101979","journal-title":"Transl Oncol"},{"issue":"20","key":"10651_CR59","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1016\/j.jacc.2025.04.014","volume":"85","author":"JA Regan","year":"2025","unstructured":"Regan JA, Kittleson MM, Khouri MG, Ruberg FL, Selvaraj S (2025) Serum transthyretin as a biomarker of treatment response in ATTR cardiomyopathy. J Am Coll Cardiol 85(20):1924\u20131926. https:\/\/doi.org\/10.1016\/j.jacc.2025.04.014","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10651_CR60","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1080\/13506129.2024.2322479","volume":"31","author":"NS Hendren","year":"2024","unstructured":"Hendren NS, De Lemos JA, Berry JD, Kozlitina J, Saelices L, Ji AX et al (2024) Circulating transthyretin and retinol binding protein 4 levels among middle-age V122I TTR carriers in the general population. Amyloid 31(2):124\u2013131. https:\/\/doi.org\/10.1080\/13506129.2024.2322479","journal-title":"Amyloid"},{"issue":"6","key":"10651_CR61","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1001\/jamacardio.2020.6623","volume":"6","author":"A Sinha","year":"2021","unstructured":"Sinha A, Zheng Y, Nannini D, Qu Y, Hou L, Shah SJ et al (2021) Association of the V122I transthyretin amyloidosis genetic variant with cardiac structure and function in middle-aged Black adults: Coronary Artery Risk Development in Young Adults (CARDIA) study. JAMA Cardiol 6(6):718\u2013722. https:\/\/doi.org\/10.1001\/jamacardio.2020.6623","journal-title":"JAMA Cardiol"},{"issue":"19","key":"10651_CR62","doi-asserted-by":"publisher","first-page":"e2036","DOI":"10.1212\/wnl.0000000000207158","volume":"100","author":"S Zampino","year":"2023","unstructured":"Zampino S, Sheikh FH, Vaishnav J, Judge D, Pan B, Daniel A et al (2023) Phenotypes associated with the Val122Ile, Leu58His, and late-onset Val30Met variants in patients with hereditary transthyretin amyloidosis. Neurology 100(19):e2036\u2013e2044. https:\/\/doi.org\/10.1212\/wnl.0000000000207158","journal-title":"Neurology"},{"issue":"8","key":"10651_CR63","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1001\/jamacardio.2023.1525","volume":"8","author":"S Selvaraj","year":"2023","unstructured":"Selvaraj S, Claggett BL, Quarta CC, Yu B, Inciardi RM, Buxbaum JN et al (2023) Age dependency of cardiovascular outcomes with the amyloidogenic pV142I transthyretin variant among Black individuals in the US. JAMA Cardiol 8(8):784\u2013788. https:\/\/doi.org\/10.1001\/jamacardio.2023.1525","journal-title":"JAMA Cardiol"},{"issue":"7","key":"10651_CR64","doi-asserted-by":"publisher","DOI":"10.1161\/circimaging.124.017761","volume":"18","author":"LD Weberling","year":"2025","unstructured":"Weberling LD, Ochs A, Benovoy M, Aus dem Siepen F, Salatzki J, Giannitsis E et al (2025) Machine learning to automatically differentiate hypertrophic cardiomyopathy, cardiac light chain, and cardiac transthyretin amyloidosis: a multicenter CMR study. Circ Cardiovasc Imaging 18(7):e017761. https:\/\/doi.org\/10.1161\/circimaging.124.017761","journal-title":"Circ Cardiovasc Imaging"},{"issue":"2","key":"10651_CR65","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1016\/s2589-7500(24)00249-8","volume":"7","author":"EK Oikonomou","year":"2025","unstructured":"Oikonomou EK, Vaid A, Holste G, Coppi A, McNamara RL, Baloescu C et al (2025) Artificial intelligence-guided detection of under-recognised cardiomyopathies on point-of-care cardiac ultrasonography: a multicentre study. Lancet Digit Health 7(2):e113\u2013e123. https:\/\/doi.org\/10.1016\/s2589-7500(24)00249-8","journal-title":"Lancet Digit Health"},{"issue":"1","key":"10651_CR66","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41746-025-01503-7","volume":"8","author":"F Hasanzadeh","year":"2025","unstructured":"Hasanzadeh F, Josephson CB, Waters G, Adedinsewo D, Azizi Z, White JA (2025) Bias recognition and mitigation strategies in artificial intelligence healthcare applications. NPJ Digit Med 8(1):154. https:\/\/doi.org\/10.1038\/s41746-025-01503-7","journal-title":"NPJ Digit Med"},{"issue":"11","key":"10651_CR67","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1001\/jamacardio.2024.2190","volume":"9","author":"N Aung","year":"2024","unstructured":"Aung N, Nicholls HL, Chahal CAA, Khanji MY, Rauseo E, Chadalavada S et al (2024) Prevalence, cardiac phenotype, and outcomes of transthyretin variants in the UK biobank population. JAMA Cardiol 9(11):964\u2013972. https:\/\/doi.org\/10.1001\/jamacardio.2024.2190","journal-title":"JAMA Cardiol"},{"issue":"9","key":"10651_CR68","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1002\/ejhf.2606","volume":"24","author":"L Chacko","year":"2022","unstructured":"Chacko L, Karia N, Venneri L, Bandera F, Passo BD, Buonamici L et al (2022) Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis. Eur J Heart Fail 24(9):1700\u20131712. https:\/\/doi.org\/10.1002\/ejhf.2606","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10651_CR69","doi-asserted-by":"publisher","first-page":"3942","DOI":"10.1002\/ehf2.12989","volume":"7","author":"S Law","year":"2020","unstructured":"Law S, Petrie A, Chacko L, Cohen OC, Ravichandran S, Gilbertson JA et al (2020) Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage. ESC Heart Fail 7(6):3942\u20133949. https:\/\/doi.org\/10.1002\/ehf2.12989","journal-title":"ESC Heart Fail"},{"issue":"4","key":"10651_CR70","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/ejhf.2776","volume":"25","author":"A Porcari","year":"2023","unstructured":"Porcari A, Razvi Y, Masi A, Patel R, Ioannou A, Rauf MU et al (2023) Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy. Eur J Heart Fail 25(4):515\u2013524. https:\/\/doi.org\/10.1002\/ejhf.2776","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"10651_CR71","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1002\/ejhf.2589","volume":"24","author":"AS Antonopoulos","year":"2022","unstructured":"Antonopoulos AS, Panagiotopoulos I, Kouroutzoglou A, Koutsis G, Toskas P, Lazaros G et al (2022) Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis. Eur J Heart Fail 24(9):1677\u20131696. https:\/\/doi.org\/10.1002\/ejhf.2589","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10651_CR72","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1001\/jamacardio.2024.4578","volume":"10","author":"A Ioannou","year":"2024","unstructured":"Ioannou A, Razvi Y, Porcari A, Rauf MU, Martinez-Naharro A, Venneri L et al (2024) Kidney outcomes in transthyretin amyloid cardiomyopathy. JAMA Cardiol 10(1):50\u201358. https:\/\/doi.org\/10.1001\/jamacardio.2024.4578","journal-title":"JAMA Cardiol"},{"issue":"1","key":"10651_CR73","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s40119-023-00344-3","volume":"13","author":"J Gonz\u00e1lez-Moreno","year":"2024","unstructured":"Gonz\u00e1lez-Moreno J, Dispenzieri A, Grogan M, Coelho T, Tournev I, Waddington-Cruz M et al (2024) Clinical and genotype characteristics and symptom migration in patients with mixed phenotype transthyretin amyloidosis from the transthyretin amyloidosis outcomes survey. Cardiol Ther 13(1):117\u2013135. https:\/\/doi.org\/10.1007\/s40119-023-00344-3","journal-title":"Cardiol Ther"},{"issue":"5","key":"10651_CR74","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.cjco.2025.03.002","volume":"7","author":"N Fine","year":"2025","unstructured":"Fine N, Ducharme A, Matte G, Mezei M, Bril V, Delgado D (2025) Diagnosis and management of mixed phenotype hereditary transthyretin amyloidosis: a case-based, Canadian perspective. CJC Open 7(5):614\u2013627. https:\/\/doi.org\/10.1016\/j.cjco.2025.03.002","journal-title":"CJC Open"},{"issue":"6","key":"10651_CR75","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/ejhf.2198","volume":"23","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, Bengel F, Brito D, Damy T, Duca F, Dorbala S et al (2021) Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy. Eur J Heart Fail 23(6):895\u2013905. https:\/\/doi.org\/10.1002\/ejhf.2198","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"10651_CR76","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1002\/ejhf.3339","volume":"26","author":"SA Muller","year":"2021","unstructured":"Muller SA, Peir\u00f3-Aventin B, Biagioni G, Tini G, Saturi G, Kronberger C et al (2021) Evaluation of the 2021 ESC recommendations for family screening in hereditary transthyretin cardiac amyloidosis. Eur J Heart Fail 26(9):2025\u20132034. https:\/\/doi.org\/10.1002\/ejhf.3339","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10651_CR77","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1080\/13506129.2023.2227322","volume":"30","author":"G Albenque","year":"2023","unstructured":"Albenque G, Bezard M, Kharoubi M, Odouard S, Lunati A, Poullot E et al (2023) Comparison of cardiac involvement, extracardiac manifestations and outcomes between homozygote and heterozygote transthyretin p.Val142Ile (V122I) variant in patients with hereditary transthyretin amyloidosis: a cohort study. Amyloid 30(4):407\u2013415. https:\/\/doi.org\/10.1080\/13506129.2023.2227322","journal-title":"Amyloid"},{"issue":"2","key":"10651_CR78","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","volume":"390","author":"JD Gillmore","year":"2024","unstructured":"Gillmore JD, Judge DP, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S et al (2024) Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med 390(2):132\u2013142. https:\/\/doi.org\/10.1056\/NEJMoa2305434","journal-title":"N Engl J Med"},{"issue":"11","key":"10651_CR79","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M et al (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379(11):1007\u20131016. https:\/\/doi.org\/10.1056\/NEJMoa1805689","journal-title":"N Engl J Med"},{"key":"10651_CR80","unstructured":"US Food and Drug Administration (2023) VYNDAQEL and VYNDAMAX. Highlights of Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/211996s002,212161s002lbl.pdf. Accessed 4 June 2026"},{"key":"10651_CR81","unstructured":"US Food and Drug Administration (2024) ATTRUBY. Highlights of Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/216540s000lbl.pdf.\u00a0Accessed 4\u00a0June 2026"},{"key":"10651_CR82","unstructured":"US Food and Drug Administration (2025) AMVUTTRA. Highlights of Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215515s006lbl.pdf.\u00a0Accessed 4 June 2026"},{"key":"10651_CR83","unstructured":"US Food and Drug Administration (2025) ONPATTRO. Highlights of Prescribing Information. https:\/\/www.alnylam.com\/sites\/default\/files\/pdfs\/ONPATTRO-Prescribing-Information.pdf. Accessed 4\u00a0June 2026"},{"key":"10651_CR84","unstructured":"US Food and Drug Administration (2026) WAINUA. Highlights of Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/217388s005lbl.pdf. Accessed 4 June 2026"},{"issue":"1","key":"10651_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","volume":"30","author":"D Adams","year":"2023","unstructured":"Adams D, Tournev IL, Taylor MS, Coelho T, Plante-Bordeneuve V, Berk JL et al (2023) Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid 30(1):1\u20139. https:\/\/doi.org\/10.1080\/13506129.2022.2091985","journal-title":"Amyloid"},{"issue":"15","key":"10651_CR86","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1001\/jama.2023.18688","volume":"330","author":"T Coelho","year":"2023","unstructured":"Coelho T, Marques W Jr, Dasgupta NR, Chao CC, Parman Y, Fran\u00e7a MC Jr et al (2023) Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy. JAMA 330(15):1448\u20131458. https:\/\/doi.org\/10.1001\/jama.2023.18688","journal-title":"JAMA"},{"issue":"1","key":"10651_CR87","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2409134","volume":"392","author":"M Fontana","year":"2025","unstructured":"Fontana M, Berk JL, Gillmore JD, Witteles RM, Grogan M, Drachman B et al (2025) Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. N Engl J Med 392(1):33\u201344. https:\/\/doi.org\/10.1056\/NEJMoa2409134","journal-title":"N Engl J Med"},{"key":"10651_CR88","unstructured":"ClinicalTrials.gov (2020) CARDIO-TTRansform: A study to evaluate the efficacy and safety of eplontersen (formerly known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in participants with transthyretin-mediated amyloid cardiomyopathy (ATTR CM). https:\/\/clinicaltrials.gov\/study\/NCT04136171.\u00a0Accessed 13 Mar 2026"},{"key":"10651_CR89","unstructured":"ClinicalTrials.gov (2026) TRITON-CM: a study to evaluate nucresiran in patients with transthyretin amyloidosis with cardiomyopathy. https:\/\/clinicaltrials.gov\/study\/NCT07052903.\u00a0Accessed 13 Mar 2026"},{"key":"10651_CR90","unstructured":"ClinicalTrials.gov (2026) TRITON-PN: a study to evaluate the efficacy and safety of nucresiran in patients with hereditary transthyretin amyloidosis with polyneuropathy (TRITON-PN). https:\/\/clinicaltrials.gov\/study\/NCT07223203. Accessed 13\u00a0Mar 2026"},{"issue":"1","key":"10651_CR91","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13023-024-03198-7","volume":"19","author":"TN Qarni","year":"2024","unstructured":"Qarni TN, Jones FJS, Drachman B, Khella S, Pieretti J, Bustamante NS et al (2024) Treatment characteristics of patients with hereditary transthyretin amyloidosis: a cohort study. Orphanet J Rare Dis 19(1):191. https:\/\/doi.org\/10.1186\/s13023-024-03198-7","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"10651_CR92","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.jacc.2024.11.015","volume":"85","author":"M Fontana","year":"2025","unstructured":"Fontana M, Maurer MS, Gillmore JD, Bender S, Aldinc E, Eraly SA et al (2025) Outpatient worsening heart failure in patients with transthyretin amyloidosis with cardiomyopathy in the HELIOS-B trial. J Am Coll Cardiol 85(7):753\u2013761. https:\/\/doi.org\/10.1016\/j.jacc.2024.11.015","journal-title":"J Am Coll Cardiol"},{"key":"10651_CR93","doi-asserted-by":"crossref","unstructured":"Soman P, Garcia-Pavia P, Gillmore J, Adams D, Conceicao I, Coelho T et al (2024) Rationale & design of ACT-EARLY, the Acoramidis Transthyretin Amyloidosis Prevention Trial: early detection using cardiac radionuclide imaging. The 29th Annual Scientific Session of the American Society of Nuclear Cardiology; Austin, TX, USA. J Nucl Cardiol 101948","DOI":"10.1016\/j.nuclcard.2024.101948"},{"key":"10651_CR94","unstructured":"ClinicalTrials.gov (2026) Acoramidis transthyretin amyloidosis prevention trial in the young (ACT-EARLY) study in asymptomatic carriers of a Pathogenic TTR variant. https:\/\/clinicaltrials.gov\/study\/NCT06563895.\u00a0Accessed 16 Jan 2026"},{"issue":"23","key":"10651_CR95","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1056\/NEJMoa2412309","volume":"391","author":"M Fontana","year":"2024","unstructured":"Fontana M, Solomon SD, Kachadourian J, Walsh L, Rocha R, Lebwohl D et al (2024) CRISPR-Cas9 gene editing with nexiguran ziclumeran for ATTR cardiomyopathy. N Engl J Med 391(23):2231\u20132241. https:\/\/doi.org\/10.1056\/NEJMoa2412309","journal-title":"N Engl J Med"},{"key":"10651_CR96","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2510209","author":"JD Gillmore","year":"2025","unstructured":"Gillmore JD, Gane E, T\u00e4ubel J, Pilebro B, Echaniz-Laguna A, Kao J et al (2025) Nexiguran ziclumeran gene editing in hereditary ATTR with polyneuropathy. N Engl J Med 393(14):1375\u20131386. https:\/\/doi.org\/10.1056\/NEJMoa2510209","journal-title":"N Engl J Med"},{"key":"10651_CR97","unstructured":"ClinicalTrials.gov (2025) MAGNITUDE: A phase 3 study of NTLA-2001 in participants with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). https:\/\/clinicaltrials.gov\/study\/NCT06128629.\u00a0Accessed 13 Mar 2026"},{"key":"10651_CR98","unstructured":"ClinicalTrials.gov (2025) A phase 3 study of NTLA-2001 in ATTRv-PN. https:\/\/clinicaltrials.gov\/study\/NCT06672237.\u00a0Accessed 13 Mar 2026"},{"key":"10651_CR99","unstructured":"ClinicalTrials.gov (2026) CLEOPATTRA: a research study to look at the effects of treatment with a medicine called coramitug (NNC6019-0001) in people with heart failure due to transthyretin amyloid (ATTR) amyloidosis (CLEOPATTRA). https:\/\/clinicaltrials.gov\/study\/NCT07207811.\u00a0Accessed 13 Mar 2026"},{"issue":"6","key":"10651_CR100","doi-asserted-by":"publisher","DOI":"10.1007\/s12170-021-00670-y","volume":"15","author":"G Spencer-Bonilla","year":"2021","unstructured":"Spencer-Bonilla G, Njoroge JN, Pearson K, Witteles RM, Aras MA, Alexander KM (2021) Racial and ethnic disparities in transthyretin cardiac amyloidosis. Curr Cardiovasc Risk Rep 15(6):8. https:\/\/doi.org\/10.1007\/s12170-021-00670-y","journal-title":"Curr Cardiovasc Risk Rep"},{"issue":"11","key":"10651_CR101","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/j.cardfail.2024.04.019","volume":"30","author":"A Wardhere","year":"2024","unstructured":"Wardhere A, Bampatsias D, Cohn E, Fine D, Freitas C, Gallegos C et al (2024) Unlocking diversity in cardiovascular clinical research: lessons from the screening for cardiac amyloidosis with nuclear imaging in a minority populations study. J Card Fail 30(11):1507\u20131511. https:\/\/doi.org\/10.1016\/j.cardfail.2024.04.019","journal-title":"J Card Fail"},{"issue":"3","key":"10651_CR102","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1177\/1740774516631735","volume":"13","author":"TM Ramsey","year":"2016","unstructured":"Ramsey TM, Snyder JK, Lovato LC, Roumie CL, Glasser SP, Cosgrove NM et al (2016) Recruitment strategies and challenges in a large intervention trial: systolic blood pressure intervention trial. Clin Trials 13(3):319\u2013330. https:\/\/doi.org\/10.1177\/1740774516631735","journal-title":"Clin Trials"},{"key":"10651_CR103","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare13111217","author":"N Bacour","year":"2025","unstructured":"Bacour N, Grewal S, Ploem MC, Suurmond J, Klautz RJM, Grewal N (2025) Bridging barriers: engaging ethnic minorities in cardiovascular research. Healthcare (Basel). https:\/\/doi.org\/10.3390\/healthcare13111217","journal-title":"Healthcare (Basel)"},{"issue":"3","key":"10651_CR104","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/mus.28026","volume":"69","author":"C Karam","year":"2024","unstructured":"Karam C, Mauermann ML, Gonzalez-Duarte A, Kaku MC, Ajroud-Driss S, Brannagan TH 3rd et al (2024) Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States: recommendations from a panel of experts. Muscle Nerve 69(3):273\u2013287. https:\/\/doi.org\/10.1002\/mus.28026","journal-title":"Muscle Nerve"},{"issue":"9","key":"10651_CR105","doi-asserted-by":"publisher","DOI":"10.1161\/circheartfailure.119.006075","volume":"12","author":"MS Maurer","year":"2019","unstructured":"Maurer MS, Bokhari S, Damy T, Dorbala S, Drachman BM, Fontana M et al (2019) Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Heart Fail 12(9):e006075. https:\/\/doi.org\/10.1161\/circheartfailure.119.006075","journal-title":"Circ Heart Fail"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10651-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-026-10651-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10651-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T02:45:22Z","timestamp":1782960322000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-026-10651-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":105,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10651"],"URL":"https:\/\/doi.org\/10.1007\/s10741-026-10651-1","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"19 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Prof Ferdinand is a consultant for Boehringer Ingelheim, Eli Lilly, Janssen, Medtronic, and Novartis. Dr Selvaraj receives research support from the National Heart, Lung, and Blood Institute (K23 HL161348 and 1R03HL180898-01), American Heart Association (#935275), American Academy of CME, Winn Foundation, and the Foundation for Sarcoidosis Research. He is a consultant to AstraZeneca and BridgeBio Pharma. He is a Steering Committee member for the TTRANSLATE-ATTR trial independently overseen by the American Heart Association and financially supported by AstraZeneca. Dr Malhotra is a consultant and has participated in advisory boards for Pfizer Inc., AstraZeneca, BridgeBio, and Alnylam Pharmaceuticals. He has received payment or honoraria for speaker bureaus for Pfizer Inc., AstraZeneca, Alnylam Pharmaceuticals, and BridgeBio. Dr Alexander has been a consultant for Alexion, Alnylam, BridgeBio, Bayer, Novo Nordisk, and Pfizer Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"77"}}